View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
July 26, 1994


By CBR Staff Writer

London-based medical software developer Clinical Computing Plc couldn’t have made a much worse start in life as a public company, yesterday announcing its first interim results since its February flotation, and showing a big loss on slumping sales. The figures were so bad that the shares plunged 32 pence to 68 pence when the market opened, and for a time prices shown were indicative, meaning that market makers were not obliged to trade at the prices they were showing. Clinical’s turnover plunged to ?740,000 from ?1.18m this time last year and it made a ?23,000 loss against a profit last time of ?45,000. The company’s statement said that major investment and delays in customers placing orders caused a reduction in turnover which resulted in the loss, but everybody at the company was closeted in board meetings all day yesterday and no-one was available to shed any further light on a deeply embarrassing maiden set of interim figures. The company was valued at ?20m at its flotation price of 124 pence a share and has been up to 186p.

Content from our partners
DTX Manchester welcomes leading tech talent from across the region and beyond
The hidden complexities of deploying AI in your business
When it comes to AI, remember not every problem is a nail

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.